Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Form 8-K

sec.gov

8-K — Ernexa Therapeutics Inc.

Accession: 0001493152-26-031930

Filed: 2026-07-02

Period: 2026-07-02

CIK: 0000748592

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

GRAPHIC (ex99-1_002.jpg)

GRAPHIC (ex99-1_003.jpg)

GRAPHIC (ex99-1_004.jpg)

GRAPHIC (ex99-1_005.jpg)

GRAPHIC (ex99-1_006.jpg)

GRAPHIC (ex99-1_007.jpg)

GRAPHIC (ex99-1_008.jpg)

GRAPHIC (ex99-1_009.jpg)

GRAPHIC (ex99-1_010.jpg)

GRAPHIC (ex99-1_011.jpg)

GRAPHIC (ex99-1_012.jpg)

GRAPHIC (ex99-1_013.jpg)

GRAPHIC (ex99-1_014.jpg)

GRAPHIC (ex99-1_015.jpg)

GRAPHIC (ex99-1_016.jpg)

GRAPHIC (ex99-1_017.jpg)

GRAPHIC (ex99-1_018.jpg)

GRAPHIC (ex99-1_019.jpg)

GRAPHIC (ex99-1_020.jpg)

GRAPHIC (ex99-1_021.jpg)

GRAPHIC (ex99-1_022.jpg)

GRAPHIC (ex99-1_023.jpg)

GRAPHIC (ex99-1_024.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000748592

0000748592

2026-07-02

2026-07-02

0000748592

ERNA:CommonStockParValue0.005PerShareMember

2026-07-02

2026-07-02

0000748592

ERNA:CommonStockPurchaseWarrantsMember

2026-07-02

2026-07-02

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date

of Report (Date of earliest event reported): July 2, 2026

Ernexa

Therapeutics Inc.

(Exact

Name of Registrant as Specified in its Charter)

Delaware

001-11460

31-1103425

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1035

Cambridge Street, Suite 18A

Cambridge,

MA

02141

(Address

of Principal Executive Offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (617) 798-6700

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

symbol

Name

of each exchange on which registered

Common

Stock, par value $0.005 per share

ERNA

The

Nasdaq Stock Market LLC

Common

Stock Purchase Warrants

ERNAW

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2

of the Securities Exchange Act of 1934:

Emerging

growth company ☐

If

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

7.01 Regulation

FD Disclosure.

On

July 2, 2026, Ernexa Therapeutics Inc., a Delaware corporation (the “Company”, “we”, “us”,

or “our”), made available an updated presentation for investors. This presentation updates the presentation

posted on February 26, 2026. A copy of this updated presentation is attached hereto as Exhibit 99.1 and incorporated by reference in

this Item 7.01. A copy of the presentation will also be available on our website at https://investor.ernexatx.com

on July 3, 2026.

Without

limiting the generality of the foregoing, the “Forward-Looking Statements” disclosure contained in the Investor Presentation

is incorporated by reference into this Item 7.01.

Use

of our Website to Distribute Material Company Information

We

use our website as a channel of distribution for important Company information. We routinely post on our website important information,

including press releases, investor presentations and financial information, which may be accessed by clicking on either the “News”

or “Investor Relations” sections of www.ernexatx.com. We may also use our website to expedite public access to time-critical

information regarding our Company in advance of or in lieu of distributing a press release or a filing with the Securities and Exchange

Commission (the “SEC”) disclosing the same information. Therefore, investors should look to the “News”

or “Investor Relations” sections of our website for important and time-critical information. Visitors to our website can

also register to receive automatic e-mail and other notifications alerting them when certain new information is made available on our

website. Information contained on, or accessible through, our website is not a part of and is not incorporated by reference in this Current

Report on Form 8-K or in any of our other filings with the SEC.

The

information contained in this Item 7.01, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed”

for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise

subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange

Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.

Item

9.01 Financial

Statements and Exhibits.

(d)

Exhibits.

Exhibit

Number

Description

99.1

Ernexa Therapeutics Investor Presentation – July 2026.

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

-2-

SIGNATURE

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned, hereunto duly authorized.

Ernexa

Therapeutics Inc.

Dated:

July 2, 2026

By:

/s/

Sanjeev Luther

Sanjeev

Luther

President

and Chief Executive Officer

-3-

EX-99.1

EX-99.1

Filename: ex99-1.htm · Sequence: 2

Exhibit 99.1

GRAPHIC

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 3

Binary file (386911 bytes)

Download ex99-1_001.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_002.jpg · Sequence: 4

Binary file (1123617 bytes)

Download ex99-1_002.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_003.jpg · Sequence: 5

Binary file (425688 bytes)

Download ex99-1_003.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_004.jpg · Sequence: 6

Binary file (716695 bytes)

Download ex99-1_004.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_005.jpg · Sequence: 7

Binary file (827115 bytes)

Download ex99-1_005.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_006.jpg · Sequence: 8

Binary file (798831 bytes)

Download ex99-1_006.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_007.jpg · Sequence: 9

Binary file (645893 bytes)

Download ex99-1_007.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_008.jpg · Sequence: 10

Binary file (839425 bytes)

Download ex99-1_008.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_009.jpg · Sequence: 11

Binary file (501816 bytes)

Download ex99-1_009.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_010.jpg · Sequence: 12

Binary file (558535 bytes)

Download ex99-1_010.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_011.jpg · Sequence: 13

Binary file (571868 bytes)

Download ex99-1_011.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_012.jpg · Sequence: 14

Binary file (919288 bytes)

Download ex99-1_012.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_013.jpg · Sequence: 15

Binary file (484467 bytes)

Download ex99-1_013.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_014.jpg · Sequence: 16

Binary file (495494 bytes)

Download ex99-1_014.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_015.jpg · Sequence: 17

Binary file (491141 bytes)

Download ex99-1_015.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_016.jpg · Sequence: 18

Binary file (454208 bytes)

Download ex99-1_016.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_017.jpg · Sequence: 19

Binary file (570321 bytes)

Download ex99-1_017.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_018.jpg · Sequence: 20

Binary file (672945 bytes)

Download ex99-1_018.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_019.jpg · Sequence: 21

Binary file (456956 bytes)

Download ex99-1_019.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_020.jpg · Sequence: 22

Binary file (481678 bytes)

Download ex99-1_020.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_021.jpg · Sequence: 23

Binary file (418683 bytes)

Download ex99-1_021.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_022.jpg · Sequence: 24

Binary file (604883 bytes)

Download ex99-1_022.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_023.jpg · Sequence: 25

Binary file (718816 bytes)

Download ex99-1_023.jpg

GRAPHIC

GRAPHIC

Filename: ex99-1_024.jpg · Sequence: 26

Binary file (753000 bytes)

Download ex99-1_024.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 43

v3.26.1

Cover

Jul. 02, 2026

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jul. 02, 2026

Entity File Number

001-11460

Entity Registrant Name

Ernexa

Therapeutics Inc.

Entity Central Index Key

0000748592

Entity Tax Identification Number

31-1103425

Entity Incorporation, State or Country Code

DE

Entity Address, Address Line One

1035

Cambridge Street

Entity Address, Address Line Two

Suite 18A

Entity Address, City or Town

Cambridge

Entity Address, State or Province

MA

Entity Address, Postal Zip Code

02141

City Area Code

(617)

Local Phone Number

798-6700

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock, par value $0.005 per share

Title of 12(b) Security

Common

Stock, par value $0.005 per share

Trading Symbol

ERNA

Security Exchange Name

NASDAQ

Common Stock Purchase Warrants

Title of 12(b) Security

Common

Stock Purchase Warrants

Trading Symbol

ERNAW

Security Exchange Name

NASDAQ

X

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

na

Period Type:

duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

na

Period Type:

duration

X

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

na

Period Type:

duration

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=ERNA_CommonStockParValue0.005PerShareMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type:

X

- Details

Name:

us-gaap_StatementClassOfStockAxis=ERNA_CommonStockPurchaseWarrantsMember

Namespace Prefix:

Data Type:

na

Balance Type:

Period Type: